Sentiment-Signal
6,5
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 26.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 17.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain |
| 24.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O |
| 31.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Of |
| 20.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O |
Stammdaten
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | Contineum Therapeutics, Inc. |
|---|---|
| Ticker | CTNM |
| CIK | 0001855175 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 450,4 Mio. USD |
| Beta | 1,39 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -59,978,000 | -2.17 | 276,642,000 | 260,989,000 | |
| 2025-09-30 | 10-Q | -12,792,000 | 190,847,000 | 180,470,000 | ||
| 2025-06-30 | 10-Q | -16,040,000 | 182,888,000 | 171,390,000 | ||
| 2025-03-31 | 10-Q | -15,990,000 | 198,264,000 | 184,768,000 | ||
| 2024-12-31 | 10-K | 0 | -42,258,000 | -2.18 | 212,847,000 | 198,066,000 |
| 2024-09-30 | 10-Q | 0 | -10,267,000 | -0.40 | 216,034,000 | 210,228,000 |
| 2024-06-30 | 10-Q | 0 | -9,009,000 | -0.39 | 221,355,000 | 217,503,000 |
| 2024-03-31 | 10-Q | -8,417,000 | 123,564,000 | -75,629,000 | ||
| 2023-12-31 | 10-K | 50,000,000 | 22,720,000 | 0.08 | 130,386,000 | -67,936,000 |
| 2023-09-30 | 10-Q | 0 | -6,251,000 | -2.69 | -61,145,000 | |
| 2023-06-30 | 10-Q | 50,000,000 | 41,564,000 | 0.84 | -55,432,000 | |
| 2023-03-31 | 10-Q | -4,824,000 | -97,462,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-06 | Lorrain Daniel S. | Officer, Chief Scientific Officer | Open Market Sale | -4,170 | 13.43 | -56,013.94 | -147,7% | |
| 2026-03-02 | Watkins Tim | Officer, CMO & Head of Development | Open Market Sale | -3,611 | 15.02 | -54,220.25 | -143,0% | |
| 2026-03-02 | Lorrain Daniel S. | Officer, Chief Scientific Officer | Open Market Sale | -4,170 | 15.01 | -62,585.03 | -165,0% | |
| 2026-02-25 | Stengone Carmine N. | Director, Officer, CEO and President | Open Market Sale | -2,700 | 16.02 | -43,241.85 | -114,0% | |
| 2026-02-25 | Lorrain Daniel S. | Officer, Chief Scientific Officer | Open Market Sale | -3,824 | 16.01 | -61,227.98 | -161,4% | |
| 2026-02-24 | Stengone Carmine N. | Director, Officer, CEO and President | Open Market Sale | -4,400 | 16.02 | -70,485.80 | -185,8% | |
| 2026-02-24 | Lorrain Daniel S. | Officer, Chief Scientific Officer | Open Market Sale | -4,300 | 16.03 | -68,935.88 | -181,8% | |
| 2026-02-19 | Lorrain Daniel S. | Officer, Chief Scientific Officer | Open Market Sale | -100 | 16.00 | -1,600.00 | -4,2% | |
| 2026-02-11 | Lorrain Daniel S. | Officer, Chief Scientific Officer | Open Market Sale | -400 | 16.00 | -6,400.00 | -16,9% | |
| 2026-02-11 | Stengone Carmine N. | Director, Officer, CEO and President | Open Market Sale | -400 | 16.00 | -6,400.00 | -16,9% | |
| 2026-02-03 | Lorrain Daniel S. | Officer, Chief Scientific Officer | Open Market Sale | -3,000 | 14.82 | -44,468.70 | -117,2% | |
| 2026-02-03 | Lorrain Daniel S. | Officer, Chief Scientific Officer | Open Market Sale | -1,170 | 15.25 | -17,836.77 | -47,0% | |
| 2026-01-28 | Watkins Tim | Officer, CMO & Head of Development | Open Market Sale | -2,800 | 14.09 | -39,441.08 | -104,0% | |
| 2026-01-28 | Watkins Tim | Officer, CMO & Head of Development | Open Market Sale | -811 | 14.48 | -11,747.17 | -31,0% | |
| 2026-01-05 | Lorrain Daniel S. | Officer, Chief Scientific Officer | Open Market Sale | -500 | 11.13 | -5,564.90 | -14,7% | |
| 2026-01-05 | Lorrain Daniel S. | Officer, Chief Scientific Officer | Open Market Sale | -3,670 | 10.35 | -37,978.26 | -100,1% | |
| 2025-12-29 | Watkins Tim | Officer, CMO & Head of Development | Open Market Sale | -3,611 | 12.06 | -43,558.41 | -114,8% | |
| 2025-12-23 | Lorrain Daniel S. | Officer, Chief Scientific Officer | Open Market Sale | -4,170 | 12.23 | -51,009.11 | -134,5% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.